ArticleScientific reports2026
An explainable meta-learned hybrid CNN-transformer model with dual attention for leukemia diagnosis from peripheral blood smears.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Lymphoblastic Leukemia (ALL) is one of the most aggressive hematological malignancies, and its early diagnosis remains challenging due to non-specific clinical symptoms and reliance on invasive procedures such as bone marrow biopsies. To address these limitations, we propose Meta-Conformer-XAI, a novel meta-learned hybrid deep learning framework for non-invasive ALL detection using microscopic peripheral blood smear images. Unlike conventional CNN-Transformer pipelines, our approach integrates three key innovations: (1) a Dual Attention Feature Fusion (DAFF) block that adaptively combines local morphological features extracted by a CNN with global contextual dependencies captured by a Vision Transformer (ViT); (2) a Meta-Learning Path Controller, which dynamically optimizes information flow between convolutional and transformer pathways for improved generalization across heterogeneous datasets; and (3) a Reinforcement Learning-based Confidence Estimator, ensuring robust decision reliability in clinical settings. We validated the framework on two benchmark datasets, the ALL Image Dataset and the C-NMC Leukemia Dataset using both fixed train/validation/test splits and 5-fold cross-validation. To mitigate class imbalance, a class-aware augmentation strategy was employed, significantly improving minority-class recognition. Meta-Conformer-XAI achieved 0.9924 accuracy on the ALL dataset and 0.9636 accuracy on the C-NMC dataset, with AUC-ROC scores exceeding 0.99 across both, outperforming baseline CNNs, ViTs, and existing hybrid architectures. Furthermore, the framework incorporates a comprehensive explainability module combining Grad-CAM, SHAP, LIME, and Integrated Gradients, providing transparent insights into feature attribution and clinical relevance. Overall, Meta-Conformer-XAI advances the state of the art in automated leukemia diagnosis by offering a precise, interpretable, and scalable tool that addresses current limitations of diagnostic invasiveness, model generalization, and clinical trustworthiness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.